文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

Alteco LPS吸附器在脓毒性休克中的随机双盲试验:安全但无获益

Endotoxin Removal in Septic Shock with the Alteco LPS Adsorber Was Safe But Showed no Benefit Compared to Placebo in the Double-Blind Randomized Controlled Trial-the Asset Study.
PubMed 文献 · Shock · 2020-01-01
一句话结论在早期革兰阴性脓毒性休克中,LPS吸附器联合标准治疗安全但相比假吸附器无获益,内毒素水平低。

该试点、双盲、随机、IIa期可行性临床研究在六个斯堪的纳维亚ICU进行,计划纳入32例腹部或泌尿生殖道来源的脓毒性休克患者,实际纳入LPS吸附器组8例、假吸附器组7例。研究治疗在纳入后12小时内开始,前2天每天6小时。结果显示两组血浆LPS水平低且无组间差异,炎症标志物和器官功能变化相似;LPS吸附器组无28天内死亡,假吸附器组2例死亡;不良事件均判定与设备无关。结论为LPS吸附器联合标准治疗相比假吸附器无获益。

要点

  • 在早期革兰阴性脓毒性休克患者中,LPS吸附器组相比假吸附器组血浆LPS水平低且无组间差异。
  • LPS吸附器组8例中无28天内死亡,假吸附器组7例中2例死亡,但研究为小样本试点可行性研究。
  • 两组炎症标志物和器官功能变化相似,LPS吸附器相比假吸附器无获益。
  • LPS吸附器组3例、假吸附器组2例报告共21项不良事件,均判定与设备无关。

适用人群与场景

  • 早期革兰阴性脓毒性休克患者,感染来源为腹部或泌尿生殖道,纳入六个斯堪的纳维亚ICU。

处置流程与药物剂量

  • LPS吸附器治疗在纳入后12小时内开始,前2天每天6小时;对照为假吸附器(无活性LPS结合的治疗)。

研究设计与关键结果

  • 试点、双盲、随机、IIa期可行性临床研究,在六个斯堪的纳维亚ICU进行,计划纳入32例,实际LPS吸附器组8例、假吸附器组7例;研究在527天后终止。
  • LPS吸附器组3例和假吸附器组2例报告共21项不良事件,均判定与设备无关。
  • 假吸附器组2例、LPS吸附器组0例在28天内死亡。
  • 两组血浆LPS水平低且吸附治疗期间及之后无组间差异;炎症标志物和器官功能变化相似。

证据类型、等级与局限

  • 证据类型:试点、双盲、随机、IIa期可行性临床研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 在早期革兰阴性脓毒性休克中,LPS吸附器联合标准治疗相比假吸附器无获益;原文未据此给出推荐。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

PURPOSE: Lipopolysaccharides (LPS) are presumed to contribute to the inflammatory response in sepsis. We investigated if extracorporeal Alteco LPS Adsorber for LPS removal in early gram-negative septic shock was feasible and safe. Also, effects on endotoxin level, inflammatory response, and organ function were assessed.

METHODS: A pilot, double-blinded, randomized, Phase IIa, feasibility clinical investigation was undertaken in six Scandinavian intensive care units aiming to allocate 32 septic shock patients with abdominal or urogenital focus on LPS Adsorber therapy or a Sham Adsorber, therapy without active LPS binding. The study treatment was initiated within 12 h of inclusion and given for 6 h daily on first 2 days. LPS was measured in all patients.

RESULTS: The investigation was terminated after 527 days with eight patients included in the LPS Adsorber group and seven in the Sham group. Twenty-one adverse effects, judged not to be related to the device, were reported in three patients in the LPS Adsorber group and two in the Sham group. Two patients in the Sham group and no patients in the LPS Adsorber group died within 28 days. Plasma LPS levels were low without groups differences during or after adsorber therapy. The changes in inflammatory markers and organ function were similar in the groups.

CONCLUSIONS: In a small cohort of patients with presumed gram-negative septic shock, levels of circulating endotoxin were low and no adverse effects within 28 days after LPS adsorber-treatment were observed. No benefit compared with a sham device was seen when using a LPS adsorber in addition to standard care.

TRIAL REGISTRATION: Clinicaltrials.gov NCT02335723. Registered: November 28, 2014.

来源:Shock,查看原文。版权归原作者所有。

参考来源

  1. Lipcsey M, Tenhunen J, Pischke SE, et al. Endotoxin Removal in Septic Shock with the Alteco LPS Adsorber Was Safe But Showed no Benefit Compared to Placebo in the Double-Blind Randomized Controlled Trial-the Asset Study. Shock. 2020. PMID: 31880758. doi:10.1097/SHK.0000000000001503

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。